Published in Br J Cancer on July 03, 2006
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol (2008) 1.06
In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther (2008) 0.99
Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol (2014) 0.92
Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer (2009) 0.89
The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer (2011) 0.87
A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag (2007) 0.78
The use of capecitabine in daily practice: a study on adherence and patients' experiences. Patient Prefer Adherence (2012) 0.77
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer (2007) 0.75
Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Front Pharmacol (2016) 0.75
Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy. BMC Health Serv Res (2016) 0.75
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol (2014) 0.75
Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool. Health Qual Life Outcomes (2015) 0.75
Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Surg Today (2017) 0.75
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.89
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.13
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer (2002) 1.61
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer (2002) 1.35
Epidemiology, treatment and chemoprevention in colorectal cancer. Ann Oncol (2003) 1.24
Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol) (1997) 1.24
ABC of colorectal cancer: treatment of advanced disease. BMJ (2000) 1.04
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess (2003) 0.99
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer (2002) 0.91
A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics (2003) 0.90
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer (1999) 0.85
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess (2001) 0.85
Impact of uracil/tegafur plus oral calcium folinate on resource utilization. Oncology (Williston Park) (1999) 0.81
A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology (Williston Park) (1997) 0.81
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 2.00
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg (2001) 1.74
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet (2002) 1.68
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer (2002) 1.61
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Controlled trial of Iodosorb in chronic venous ulcers. Br Med J (Clin Res Ed) (1985) 1.49
Acute respiratory illness among immunized and nonimmunized patients with high-risk factors during a split season of influenza A and B. J Infect Dis (1988) 1.46
Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut (2001) 1.43
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer (1991) 1.42
Randomized, controlled trial of the double setup tracheal tube during fibreoptic orotracheal intubation under general anaesthesia. Br J Anaesth (2004) 1.40
Absorption of crystalline folic acid in man. Lancet (1968) 1.35
Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol (2001) 1.35
SOME NOTES ON THE CARDIAC CLUB. Br Heart J (1939) 1.30
Identification of an abnormal esophageal clearance response to intraluminal distention in patients with esophagitis. Gastroenterology (1992) 1.19
Oesophageal manometry and pH recording does not predict the bad results of Nissen fundoplication. Br J Surg (1990) 1.17
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology (2002) 1.15
Initiator and upstream elements in the alpha2-tubulin promoter of Giardia lamblia. Mol Biochem Parasitol (2001) 1.14
History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control (2005) 1.12
Identification of de novo chromosomal markers and derivatives by spectral karyotyping. Hum Genet (1998) 1.11
Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol (1981) 1.10
The lower oesophageal sphincter after floppy Nissen fundoplication. Br J Surg (1987) 1.04
Differential expression of estrogen receptor-alpha and -beta and androgen receptor in the ovaries of marmosets and humans. Biol Reprod (2000) 1.03
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess (2003) 0.99
Incidence of Duchenne muscular dystrophy in New South Wales and Australian Capital Territory. J Med Genet (1980) 0.99
Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol (2000) 0.99
Scintigraphic assessment of oesophageal motility: what does it show and how reliable is it? Gut (1986) 0.99
Antineoplastic agents 453. Synthesis of pancratistatin prodrugs. Anticancer Drug Des (2000) 0.99
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. Health Technol Assess (2010) 0.98
Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. Cancer Res (1991) 0.97
Amblyopia and quality of life: a systematic review. Eye (Lond) (2011) 0.95
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess (2004) 0.94
The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis (1997) 0.93
Temperature-dependent sex determination in the red-eared slider turtle, Trachemys scripta. J Exp Zool (1998) 0.93
The clinical effectiveness and safety of prophylactic retinal interventions to reduce the risk of retinal detachment and subsequent vision loss in adults and children with Stickler syndrome: a systematic review. Health Technol Assess (2011) 0.92
Recurrent reflux and wrap disruption after Nissen fundoplication: detection, incidence and timing. Br J Surg (1990) 0.92
Designing phase II trials in cancer: a systematic review and guidance. Br J Cancer (2011) 0.91
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer (2012) 0.90
Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol (2007) 0.89
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer (2002) 0.89
Variable distributions of serum creatine kinase reference values. Relationship to exercise activity. J Neurol Sci (1985) 0.89
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. Br J Dermatol (2014) 0.87
Cyanide toxicity following nitroprusside induced hypotension. Can Anaesth Soc J (1977) 0.86
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. Br J Cancer (2003) 0.85
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess (2001) 0.85
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer (2006) 0.84
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess (2009) 0.82
Poly(A) RNA populations, polypeptide synthesis and macromolecule accumulation in the cell cycle of the eukaryote Chlorella. J Cell Sci (1982) 0.82
Reproductive patterns and thalassaemia major. J Biosoc Sci (1986) 0.81
Diminished oesophageal traction forces with swallowing in gastro-oesophageal reflux disease and in functional dysphagia. Gut (1994) 0.81
The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies--I. Int J Nucl Med Biol (1982) 0.81
Chromosome 3p deletions in head and neck carcinomas: statistical ascertainment of allelic loss. Cancer Res (1992) 0.80
A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. Eur J Cancer (1997) 0.79
Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol (1998) 0.79
Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol (2004) 0.79
Attenuation of G2-phase cell cycle checkpoint control is associated with increased frequencies of unrejoined chromosome breaks in human tumor cells. Radiat Res (1996) 0.78
The Treatment of Infective Endocarditis. Proc R Soc Med (1910) 0.78
Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol (1999) 0.78
Evaluation of a teaching package designed to improve teachers' recognition of depressed pupils-a pilot study. J Adolesc (2000) 0.78
Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours. Eur J Cancer (1998) 0.78
Intravenous irinotecan plus oral ciclosporin. Clin Oncol (R Coll Radiol) (2005) 0.77
Drug abuse and dependency during pregnancy: anaesthetic issues. Anaesth Intensive Care (2007) 0.77
Multiple sites of impingement of a tracheal tube as it is advanced over a fibreoptic bronchoscope or tracheal tube introducer in anaesthetized, paralysed patients. Anaesth Intensive Care (2006) 0.77
Clinical implications of abnormal oesophageal motility. Br J Surg (1987) 0.77
Orthostatic tremor: diagnostic entity or variant of essential tremor? J Neurol Neurosurg Psychiatry (1989) 0.76
Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy. Clin Oncol (R Coll Radiol) (2010) 0.76
Are we representing the true population in oncology trials? Ann Oncol (2009) 0.75
What can the molecular pathologist offer for optimal decision making? Ann Oncol (2010) 0.75
Negative cooperativity exhibited by the lytic amino-terminal domain of human perforin: implications for perforin-mediated cell lysis. Chem Biol (1996) 0.75
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. Br J Cancer (2003) 0.75
Treating shoulder complaints in general practice. Study's results must be viewed in context of Dutch, not British, physiotherapy practice. BMJ (1997) 0.75
Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law (1997) 0.75
Concomitant medications in cancer patients: should we be more active in their management? Ann Oncol (2009) 0.75
Marijuana and memory for feelings. Prog Neuropsychopharmacol Biol Psychiatry (1982) 0.75
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br J Cancer (2001) 0.75
51Chromium studies with an IgG1 anti-Yta. Immunohematology (1991) 0.75
Time for a stock-aid. Health Serv J (1987) 0.75
THE RELATION OF SCIATICA TO THE SACRO-ILIAC JOINT. Br Med J (1923) 0.75
Staff perceptions of clozapine and their role in treatment: initial observations. J Psychosoc Nurs Ment Health Serv (1995) 0.75
CT scan of the abdomen in the evaluation of splenic infarction. J Tenn Med Assoc (1990) 0.75
Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study. Am J Clin Oncol (1989) 0.75
A Paper on SYPHILIS OF THE HEART AND AORTA. Br Med J (1929) 0.75
Preoperative ranitidine and metoclopramide. Anesth Analg (1987) 0.75
Oesophageal reflex responses: abnormalities of the enteric nervous system in patients with oesophageal symptoms. Br J Surg (1992) 0.75
Long-term outcome of octogenarians with unstable angina treated conservatively. Am J Cardiol (1995) 0.75
Atmospheric transport modelling of time resolved 133Xe emissions from the isotope production facility ANSTO, Australia. J Environ Radioact (2013) 0.75
Incidence of homozygous beta-thalassaemia in New South Wales, 1961-1976. Med J Aust (1982) 0.75
Health visiting and the nursing process. II. Putting the health visiting process into practice. Health Visit (1982) 0.75
Labs weigh price of success ... and cost of failure. Probe (Lond) (1989) 0.75
Camp nursing a change of pace. J Pract Nurs (1966) 0.75
The monark bicycle ergometer in screening arterial patients. Br J Surg (1982) 0.75
Angina Pectoris. Br Med J (1931) 0.75
Supporting young mothers. N Z Nurs J (1988) 0.75
Drug dependence in a journal club. ACP J Club (2000) 0.75
Ambulatory chemotherapy. Clin Oncol (R Coll Radiol) (1992) 0.75
A report on student health services. J Am Coll Health Assoc (1980) 0.75
Pressor inhibition of angiotensin-induced ACTH secretion. Can J Physiol Pharmacol (1987) 0.75
Classic disease descriptions in the modern curriculum. Am J Med (1989) 0.75
A comparison of the oropharyngeal leak pressure between the reusable Classic laryngeal mask airway and the single-use Soft Seal laryngeal mask airway. Anaesth Intensive Care (2006) 0.75